Lyrica rejected for fibromyalgia by the CHMP
This article was originally published in Scrip
Executive Summary
Pfizer's anticonvulsant, pregabalin (Lyrica), has received a negative opinion from the EU's CHMP for use in fibromyalgia, an additional indication. Benefits with pregabalin had not been shown in either the short or long term, the committee concluded.